On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Trading Volume Surges on Positive CLR 131 Report

Company: Cellectar Biosciences, Inc. (CLRB)
Category: News

Shares of Cellectar Biosciences (NASDAQ: CLRB) are up 9%, continuing a pre-market surge and moving on volume of 4.8 million, compared to the 30-day average of 86,851, after the company said that CLR 131 has achieved a median overall survival of 22.5 months to date in patients with multiple myeloma. The company’s ongoing phase 1 clinical trial surpasses historic published outcomes of currently marketed second and third line treatment modalities for multiple myeloma and could continue to increase over time. “We continue to make meaningful progress on our CLR 131 program and are encouraged by the observed clinical outcomes to date. We look forward to reporting data from the fourth cohort of our Phase 1 trial as well as the single and multi-dose Phase 2 study when available,” Cellectar Biosciences president and CEO Jim Caruso stated in the news release.

To view the full press release, visit: http://nnw.fm/y9LzL

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com

More from NetworkNewsBreaks

ORHub, Inc. (ORHB) Primed to Expand Medical Software into Major US Markets following Agreement with National Sales Partner

SinglePoint, Inc. (SING) Acquires $Weed Cryptocurrency

ProBility Media Corp. (PBYA) Advances on International Expansion Strategy with Acquisition of Cranbury International

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Contact us: 212.418.1217